RVLPQ (RVL Pharmaceuticals) Net Income: $-68.27 Mil (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RVLPQ RVL Pharmaceuticals PLC RVLPQ
12 GF Score
Price $0.00
View Full Analysis

What is RVL Pharmaceuticals Net Income?

RVL Pharmaceuticals RVLPQ -90.00% 12 Net Income is $-68.27 Mil as of Jun. 2023. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. RVL Pharmaceuticals's Net Income for the three months ended in Jun. 2023 was $-23.89 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-68.27 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. RVL Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $-0.24.

RVL Pharmaceuticals  (OTCPK:RVLPQ) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

RVL Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2023 is calculated as

Earnings per Share (Diluted) (Q: Jun. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Diluted Average)
=(-23.889-0)/99.370
=-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

RVL Pharmaceuticals Net Income Related Terms

RVL Pharmaceuticals Net Income Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals Net Income Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income
Get a 7-Day Free Trial -109.68 -270.90 -79.59 -64.92 -51.69

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.11 -14.45 -18.32 -11.61 -23.89
RVLPQ
12GF Score
RVL Pharmaceuticals PLC RVLPQ
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RVL Pharmaceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

RVL Pharmaceuticals's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

Net Income(A: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-51.712+0.02+0+0
=-51.69

RVL Pharmaceuticals's Net Income for the quarter that ended in Jun. 2023 is calculated as

Net Income(Q: Jun. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-24.002+0.113+0+0
=-23.89

Net Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of $-68.27 Mil mean?
RVL Pharmaceuticals (RVLPQ) has a Net Income of $-68.27 Mil as of Jun. 2023. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on RVL Pharmaceuticals and its competitors.
Is RVL Pharmaceuticals' Net Income too high?
RVL Pharmaceuticals' current Net Income is $-68.27 Mil. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' Net Income compare to SNPX and THAR?
RVL Pharmaceuticals' Net Income of $-68.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on RVL Pharmaceuticals and its competitors. RVL Pharmaceuticals's current Net Income is $-68.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current Net Income of $-68.27 Mil. The current Net Income is $-68.27 Mil. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Net Income is $-68.27 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score

Get the complete analysis for RVLPQ

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price